Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clene Inc.CLNN · Entity 7166 | Director · President & CEO | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clene Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 55,393 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 15,244 · Balance 55,393 F1: Mr. Etherington purchased 15,244 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended. |
| common stockSEC Table I · non-derivative | IndirectBy LLC | 636 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 636 F2: The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may be deemed to be beneficially owned by Mr. Etherington. |
| common stockSEC Table I · non-derivative | IndirectBy trust | 1,250 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,250 F3: The securities are owned by the Etherington Revocable Trust. Mr. Etherington is the co-trustee of the Etherington Revocable Trust. The shares owned by the Etherington Revocable Trust may be deemed to be owned by Mr. Etherington. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Etherington purchased 15,244 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.
F2: The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may be deemed to be beneficially owned by Mr. Etherington.
F3: The securities are owned by the Etherington Revocable Trust. Mr. Etherington is the co-trustee of the Etherington Revocable Trust. The shares owned by the Etherington Revocable Trust may be deemed to be owned by Mr. Etherington.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 17:41 UTC | Clene Inc. CLNN · Entity 7166 | Grantcommon stock | 15,244 | $3.28 | $50,000.32 |
DisclosureSEC source: 0001437749-26-030729 · rdgdoc.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,393 F1 · ownership.direct: Mr. Etherington purchased 15,244 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 18:23 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 65,000 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0001437749-26-020636 · rdgdoc.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: common stock · 65,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2026 as an option for 65,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:12 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 75,000 | $0.00 Strike: $5.42 | $0.00 |
DisclosureSEC source: 0001437749-26-001910 · rdgdoc.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: common stock · 75,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2026 as an option for 75,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:11 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 40,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001437749-25-030016 · rdgdoc.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: common stock · 40,000 shares Expires 2035-09-24 F1 · derivative.exercise_date: This option was granted on September 25, 2025 as an option for 40,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.05 per share. The options vest in 12 equal monthly installments on the 25th day of each calendar month, beginning October 25, 2025, until such shares are fully vested. Read SEC document |
| September 25, 2025 Filed Sep 30, 2025 19:56 UTC Amendment | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 40,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001437749-25-030107 · rdgdoc.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: common stock · 40,000 shares Expires 2035-09-24 F1 · derivative.exercise_price: This Form 4 amendment is being filed to correct a Form 4 filed on September 29, 2025. The corrected exercise price is $5.88 per share. F2 · derivative.exercise_date: This option was granted on September 25, 2025 as an option for 40,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.88 per share. The options vest in 12 equal monthly installments on the 25th day of each calendar month, beginning October 25, 2025, until such shares are fully vested. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 19:54 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001437749-25-029480 · rdgdoc.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: common stock · 10,000 shares Expires 2035-09-17 F1 · derivative.exercise_date: This option was granted on September 18, 2025 as an option for 10,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.32 per share. The options vest immediately upon grant. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:11 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 45,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-25-001592 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-02-23 F1 · derivative.exercise_date: This option was granted on February 24, 2025 as an option for 45,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.23 per share. The options vest with respect to the first 25% of such shares on February 24, 2026 and then in 36 equal installments of the balance of the shares of Common Stock on the 24th day of each calendar month thereafter beginning March 24, 2026 until such shares are fully vested. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:17 UTC | Clene Inc. CLNN · Entity 7166 | GrantWarrants (Right to buy) · Derivative | 10,000 | $0.13 Strike: $4.82 | $1,250.00 |
DisclosureSEC source: 0001562180-24-007036 · primarydocument.xml · derivative · entry 4 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-10-01 Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:17 UTC | Clene Inc. CLNN · Entity 7166 | PurchaseCommon Stock | 10,000 | $4.75 | $47,500.00 |
DisclosureSEC source: 0001562180-24-007036 · primarydocument.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,149 Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:15 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001562180-24-006354 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-08-15 F1 · derivative.exercise_date: This option was granted on August 16, 2024 as an option for 25,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.15 per share. The options vest with respect to 1/12th of such shares on September 16, 2024 and then an additional 1/12th of such options vest on the 16th day of each calendar month thereafter until such shares are fully vested. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 13:03 UTC | Clene Inc. CLNN · Entity 7166 | Exercise / conversionStock Options (Right to buy) · Derivative | 27,320 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005867 · primarydocument.xml · derivative · entry 4 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,319 Underlying: Common Stock · 27,320 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's stock option grant of 1,092,777 options to purchase common stock being reduced to 54,639 options. The exercise option price for these options was increased from $0.15 per share to $3.00 per share. F6 · shares: On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's stock option grant of 1,092,777 options to purchase common stock being reduced to 54,639 options. The exercise option price for these options was increased from $0.15 per share to $3.00 per share. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 13:03 UTC | Clene Inc. CLNN · Entity 7166 | Exercise / conversionCommon Stock | 27,320 | $3.00 | $81,960.00 |
DisclosureSEC source: 0001562180-24-005867 · primarydocument.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: On July 11, 2024, the common stock of Clene Inc. underwent a 1-for-20 reverse stock split, resulting in the reporting person's ownership in the previously disclosed 56,593 shares of common stock being reduced to 2,829 shares. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:17 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 2,250,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004897 · primarydocument.xml · derivative · entry 2 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250,000 Underlying: Common Stock · 2,250,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 2,250,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:17 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 900,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004897 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 17:49 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 900,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001562180-23-005629 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option was granted on June 29, 2023 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.90 per share. The options vest with respect to the first 25% of such shares on June 29, 2024 and then in 36 equal installments of the balance of the shares of Common Stock on the last day of each calendar month beginning July 29, 2024 until such shares are fully vested. If Clene Inc. has an NDA accepted by the FDA, 50% of the option shares shall vest on that date. If the FDA approves the accepted NDA, the then remaining unvested option shares shall vest on that date. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 12:07 UTC | Clene Inc. CLNN · Entity 7166 | PurchaseCommon Stock | 25,000 | $0.81 | $20,250.00 |
DisclosureSEC source: 0001562180-23-005506 · primarydocument.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 25,000 F1 · price: Etherington Revocable Trust purchased 25,000 shares of common stock of Clene Inc. in multiple transactions on June 26, 2023 at prices ranging from $0.80 to $0.82, inclusive, for a weighted average price of $0.81 per share. F2 · ownership.nature: The securities are owned by the Etherington Revocable Trust. Mr. Etherington is the co-trustee of the Etherington Revocable Trust. The shares owned by the Etherington Revocable Trust may be deemed to be beneficially owned by Mr. Etherington. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 22:14 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 400,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-22-007530 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-11-04 F1 · derivative.exercise_date: This option was granted on November 4, 2022 as an option for 400,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $1.11 per share. The options vest with respect to the first 25% of such shares on November 4, 2023 and then in 36 equal installments of the balance of the shares of Common Stock on the 4th day of each calendar month thereafter beginning December 4, 2023 until such shares are fully vested. Read SEC document |
| July 18, 2022 Filed Jul 19, 2022 20:08 UTC | Clene Inc. CLNN · Entity 7166 | SaleCommon Stock | 23,483 | $4.72 | $110,839.76 |
DisclosureSEC source: 0001562180-22-005708 · primarydocument.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,593 F1 · shares: The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to be sold by Mr. Etherington to satisfy tax obligations in connection with the vesting of 80,076 restricted stock awards. The sales occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan at a weighted average price of $4.72; the shares were sold in multiple transactions at prices ranging from $4.36 to $4.94, inclusive. F1 · price: The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to be sold by Mr. Etherington to satisfy tax obligations in connection with the vesting of 80,076 restricted stock awards. The sales occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan at a weighted average price of $4.72; the shares were sold in multiple transactions at prices ranging from $4.36 to $4.94, inclusive. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 13:59 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 480,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001562180-22-001500 · primarydocument.xml · derivative · entry 2 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2032-02-15 F2 · derivative.exercise_date: This option was granted on February 15, 2022 as an option for 480,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $3.04 per share. The options vest with respect to the first 25% of such shares on February 15, 2023 and then in 36 equal installments of the balance of the shares of Common Stock on the 15th day of each calendar month thereafter beginning March 15, 2023 until such shares are fully vested. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 13:59 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 69,652 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001562180-22-001500 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,652 Underlying: Common Stock · 69,652 shares Expires 2032-02-15 F1 · derivative.exercise_date: This option was granted on February 15, 2022 as an option for 69,652 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $3.04 per share. The options shall vest immediately upon grant. Read SEC document |
| November 04, 2021 Filed Nov 4, 2021 22:58 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001562180-21-006855 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-04 F1 · derivative.exercise_date: This option was granted on November 4, 2021 as an option for 100,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $4.74 per share. The options vest with respect to the first 25% of such shares on November 4, 2022 and then in 36 equal installments of Common Stock on the last day of each calendar month, beginning November 30, 2022, until such shares are fully vested Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:19 UTC | Clene Inc. CLNN · Entity 7166 | GrantCommon Stock | 80,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004605 · primarydocument.xml · nonDerivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,076 F1 · shares: This restricted stock award was granted on June 30, 2021 under the Clene Inc. 2020 Stock Plan. The award fully vests on January 15, 2022. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 21:22 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 600,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003065 · primarydocument.xml · derivative · entry 1 Etherington Robert Dee · CIK 0001835330 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2031-04-30 F1 · shares: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest with respect to the first 25% on May 31, 2022 and then in 36 equal installments of 1/48th of the balance on the last day of each calendar month, beginning June 30, 2022, until fully vested F1 · derivative.exercise_date: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest with respect to the first 25% on May 31, 2022 and then in 36 equal installments of 1/48th of the balance on the last day of each calendar month, beginning June 30, 2022, until fully vested Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.